Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
O-acetylated GD2 ganglioside is a disialoganglioside derivative with an acetyl group attached to the sialic acid residue. It is an oncofetal antigen overexpressed in various neuroectoderm-derived tumors and some carcinomas, but with limited expression in normal adult tissues, making it a promising target for immunotherapy with monoclonal antibodies and CAR-T cells. CASD1 is the enzyme responsible for the acetylation.
Monoclonal antibody binding to O-acetylated GD2; CAR-T cell targeting
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O-acetylated GD2 ganglioside.